Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial - Blauvelt, Andrew; Lacour, Jean-Philippe; Toth, Darryl; Laquer, Vivian; Beissert, Stefan; Wollenberg, Andreas; Herranz, Pedro; Pink, Andrew; Peris, Ketty; Saeki, Hidehisa (JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021)